首页> 美国卫生研究院文献>Journal of Enzyme Inhibition and Medicinal Chemistry >Synthesis and biological evaluation of benzenesulphonamide-bearing 145-trisubstituted-123-triazoles possessing human carbonic anhydrase I II IV and IX inhibitory activity
【2h】

Synthesis and biological evaluation of benzenesulphonamide-bearing 145-trisubstituted-123-triazoles possessing human carbonic anhydrase I II IV and IX inhibitory activity

机译:具有人碳酸酐酶IIIIV和IX抑制活性的含苯磺酰胺的145-三取代-123-三唑的合成与生物学评价

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

A library of benzenesulphonamides incorporating 1,2,3-triazole rings functionalised with ester, carboxylic acid, carboxamide, carboxyhydrazide, and hydroxymethyl moieties were synthesised. The carbonic anhydrase (CAs, EC 4.2.1.1) inhibitory activity of the new compounds was assessed against four human (h) isoforms, hCA I, hCA II, hCA IV, and hCA IX. Among them, hCA II and IV are anti-glaucoma drug targets, being involved in aqueous humour secretion within the eye. hCA I was inhibited with Ki’s ranging between 8.3 nM and 0.8737 µM. hCA II, the physiologically dominant cytosolic isoform, was excellently inhibited by these compounds, with Ki’s in the range of 1.6–9.4 nM, whereas hCA IV was effectively inhibited by most of them, with Ki’s in the range of 1.4–55.3 nM. Thirteen of the twenty sulphonamides were found to be excellent inhibitors of tumour associated hCA IX with Ki’s ≤ 9.5 nM. Many of the new compounds reported here showed low nM inhibitory action against hCA II, IV, and IX, isoforms involved in glaucoma and some tumours, making them interesting candidates for further medicinal chemistry/pharmacologic studies.
机译:合成了结合有被酯,羧酸,羧酰胺,羧酰肼和羟甲基部分官能化的1,2,3-三唑环的苯磺酰胺库。评估了新化合物的碳酸酐酶(CAs,EC 4.2.1.1)对四种人(h)异构体hCA I,hCA II,hCA IV和hCA IX的抑制活性。其中,hCA II和IV是抗青光眼的药物靶标,参与眼内房水的分泌。 hCA I被Ki抑制在8.3 nM和0.8737 µM之间。 hCA II,一种生理上占优势的胞质亚型,被这些化合物抑制得极好,Ki在1.6–9.4 1.6nM范围内,而hCA IV被大多数化合物有效地抑制,Ki在1.4–55.3 nM范围内。发现二十种磺酰胺中有十三种是与肿瘤相关的hCA IX的优良抑制剂,Ki's≤9.59.5nM。本文报道的许多新化合物对涉及青光眼和某些肿瘤的hCA II,IV和IX异构体均显示出低nM抑制作用,使其成为进一步药物化学/药理学研究的有趣候选物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号